Clinical Trial

PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRI

Study acronym: PRIMARY2
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This clinical trial will evaluate PSMA PET additive value for significant prostate cancer (sPCa) diagnosis in men with negative/equivocal MRI
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-11-30; most recent amendment 2026-03-01.
Status change: Recruiting → Active, Not Recruiting 2026-01-17
Status change: Not Yet Recruiting → Recruiting 2022-04-14
Trial Details
NCT Number NCT05154162
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Collaborators: St Vincent's Hospital, Sydney
Conditions Prostate Cancer
Enrollment 660 participants
Start Date 2022-03-02
Primary Completion 2025-12-15 (estimated)
Study Completion 2027-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-03